Published in Mol Pharmacol on June 25, 2008
The retinoid X receptors and their ligands. Biochim Biophys Acta (2011) 1.32
PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics (2008) 1.27
Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs). Mol Endocrinol (2009) 1.25
Overcoming drug resistance by regulating nuclear receptors. Adv Drug Deliv Rev (2010) 1.10
Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm? J Med Chem (2010) 1.09
Targeting xenobiotic receptors PXR and CAR in human diseases. Drug Discov Today (2014) 1.04
PXR antagonists and implication in drug metabolism. Drug Metab Rev (2013) 1.03
In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation. Mol Pharmacol (2011) 1.01
PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice. Diabetes (2013) 0.98
Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR. J Biol Chem (2013) 0.93
Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos (2010) 0.92
Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev (2014) 0.92
Pregnane X receptor- and CYP3A4-humanized mouse models and their applications. Br J Pharmacol (2011) 0.90
Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets. J Chem Inf Model (2015) 0.88
Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. Eur J Clin Pharmacol (2012) 0.85
Tissue-specific regulation of pregnane X receptor in cancer development and therapy. Cell Biosci (2014) 0.81
Evaluation of computational docking to identify pregnane X receptor agonists in the ToxCast database. Environ Health Perspect (2010) 0.80
Understanding nuclear receptors using computational methods. Drug Discov Today (2009) 0.80
Pregnane X receptor and drug-induced liver injury. Expert Opin Drug Metab Toxicol (2014) 0.79
Differential regulation of CYP3A4 promoter activity by a new class of natural product derivatives binding to pregnane X receptor. Biochem Pharmacol (2013) 0.78
Small-molecule modulators of PXR and CAR. Biochim Biophys Acta (2016) 0.78
Biology of PXR: role in drug-hormone interactions. EXCLI J (2014) 0.76
Exploration of the conformational landscape in pregnane X receptor reveals a new binding pocket. Protein Sci (2016) 0.75
Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res (2003) 3.72
Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science (2010) 2.99
Highly chlorinated PCBs inhibit the human xenobiotic response mediated by the steroid and xenobiotic receptor (SXR). Environ Health Perspect (2004) 2.16
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol (2004) 2.09
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res (2009) 2.01
CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos (2002) 1.94
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother (2012) 1.85
Bisphenol A and its analogues activate human pregnane X receptor. Environ Health Perspect (2012) 1.81
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol (2003) 1.79
Lack of androgenicity and estrogenicity of the three monomers used in Eastman's Tritan™ copolyesters. Food Chem Toxicol (2012) 1.76
Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality (2004) 1.69
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol (2008) 1.69
Online chemical modeling environment (OCHEM): web platform for data storage, model development and publishing of chemical information. J Comput Aided Mol Des (2011) 1.68
Gaussian mixture clustering and imputation of microarray data. Bioinformatics (2004) 1.49
Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs (2009) 1.41
Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol (2007) 1.39
Shape signatures: a new approach to computer-aided ligand- and receptor-based drug design. J Med Chem (2003) 1.39
Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res (2011) 1.31
The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol Endocrinol (2007) 1.29
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res (2012) 1.27
Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. J Clin Invest (2011) 1.27
Detecting hidden sequence propensity for amyloid fibril formation. Protein Sci (2004) 1.25
DNA microarray data imputation and significance analysis of differential expression. Bioinformatics (2005) 1.24
New predictive models for blood-brain barrier permeability of drug-like molecules. Pharm Res (2008) 1.20
Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer. Clin Cancer Res (2008) 1.18
Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proc Natl Acad Sci U S A (2011) 1.17
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res (2007) 1.15
In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective. Drug Metab Dispos (2009) 1.15
Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet (2007) 1.14
Alleviation of gut inflammation by Cdx2/Pxr pathway in a mouse model of chemical colitis. PLoS One (2012) 1.14
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos (2008) 1.14
Highly potent triazole-based tubulin polymerization inhibitors. J Med Chem (2007) 1.13
Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin Cancer Res (2007) 1.12
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol (2003) 1.12
Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res (2002) 1.10
Improved method for predicting beta-turn using support vector machine. Bioinformatics (2005) 1.10
Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists. Pharm Res (2009) 1.09
Precompetitive preclinical ADME/Tox data: set it free on the web to facilitate computational model building and assist drug development. Lab Chip (2009) 1.09
Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm? J Med Chem (2010) 1.09
Evolution of the bile salt nuclear receptor FXR in vertebrates. J Lipid Res (2008) 1.08
Trypanosoma cruzi induces edematogenic responses in mice and invades cardiomyocytes and endothelial cells in vitro by activating distinct kinin receptor (B1/B2) subtypes. FASEB J (2002) 1.06
Ligand specificity and evolution of liver X receptors. J Steroid Biochem Mol Biol (2008) 1.06
Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response. Cancer Lett (2012) 1.06
Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. Sci Transl Med (2013) 1.05
Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies. Biochem Pharmacol (2005) 1.04
Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol Cancer Ther (2002) 1.04
Shape Signatures: speeding up computer aided drug discovery. Drug Discov Today (2006) 1.03
Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology. Environ Toxicol Chem (2003) 1.03
Requirement of activated Cdc42-associated kinase for survival of v-Ras-transformed mammalian cells. Mol Cancer Res (2005) 1.03
Rhabdoid tumor growth is inhibited by flavopiridol. Clin Cancer Res (2008) 1.02
Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-κB signaling pathway. J Pharmacol Exp Ther (2013) 1.02
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res (2007) 1.01
In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation. Mol Pharmacol (2011) 1.01
Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem Res Toxicol (2008) 1.01
Autoantibody cancer biomarker: extracellular protein kinase A. Cancer Res (2006) 1.01
Using surrogate modeling in the prediction of fibrinogen adsorption onto polymer surfaces. J Chem Inf Comput Sci (2004) 1.00
Enrichment of ligands for the serotonin receptor using the Shape Signatures approach. J Chem Inf Model (2005) 1.00
Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells. Cancer Res (2008) 0.99
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res (2007) 0.99
Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. Biopolymers (2003) 0.99
Structure-based design of novel small-molecule inhibitors of Plasmodium falciparum. J Chem Inf Model (2010) 0.99
Prediction of the orientations of adsorbed protein using an empirical energy function with implicit solvation. Langmuir (2005) 0.98
Wavelet analysis of DNA walks. J Comput Biol (2006) 0.98
Carbohydrate composition of amphiphilic macromolecules influences physicochemical properties and binding to atherogenic scavenger receptor A. Acta Biomater (2012) 0.97
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol (2004) 0.97
Orphan nuclear receptors as targets for drug development. Pharm Res (2010) 0.97
Acetylation of pregnane X receptor protein determines selective function independent of ligand activation. Biochem Biophys Res Commun (2011) 0.96
Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling. Br J Nutr (2013) 0.96
A new approach to the rationale discovery of polymeric biomaterials. Biomaterials (2007) 0.96
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol (2011) 0.96
Post-translational modification of pregnane x receptor. Pharmacol Res (2011) 0.95
Development and application of hybrid structure based method for efficient screening of ligands binding to G-protein coupled receptors. J Comput Aided Mol Des (2006) 0.95
Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR. J Biol Chem (2013) 0.93
Identification of a minimal subset of receptor conformations for improved multiple conformation docking and two-step scoring. J Chem Inf Comput Sci (2004) 0.93
Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity. Cancer Res (2009) 0.93
Rapid assessment of contact-dependent secondary structure propensity: relevance to amyloidogenic sequences. Proteins (2005) 0.92
Structure-activity relationship approaches and applications. Environ Toxicol Chem (2003) 0.92
The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction. Cardiovasc Res (2004) 0.92
Prediction of Fibrinogen Adsorption for Biodegradable Polymers: Integration of Molecular Dynamics and Surrogate Modeling. Polymer (Guildf) (2007) 0.92
Paeoniflorin abrogates DSS-induced colitis via a TLR4-dependent pathway. Am J Physiol Gastrointest Liver Physiol (2013) 0.92
NetCSSP: web application for predicting chameleon sequences and amyloid fibril formation. Nucleic Acids Res (2009) 0.92
Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol Pharmacol (2013) 0.91